Nov 12, 2020 / 03:00PM GMT
Antje Witte - UCB SA - Head of IR
Good morning, good afternoon from my side. Welcome to our call introducing gene therapy. I'm happy to hand you over to Dhaval Patel, our Chief Scientific Officer, who will give you a brief presentation and who then, in the Q&A session, will be joined by his team, namely Martin Citron, Head of Neurology Therapeutic Area; and Roger Palframan, Head of External Innovation & U.S. Discovery Science.
This presentation and following Q&A session is covered by this disclaimer and safe harbor statement. We kindly ask you to read this carefully, perhaps not now, but it's also available on our website, and be informed about this.
I'm now happy to give over -- to hand over to our Chief Scientific Officer, Dhaval Patel. Thank you very much.
Dhavalkumar D. Patel - UCB SA - Executive VP & Chief Scientific Officer
Hey, everybody. Thanks for taking the time to join. It's my pleasure to speak to you today about UCB's entry into gene therapy.
As you all know, we have a strong legacy in the chemical
Ucb SA Analysts and Investors Conference Call Transcript
Nov 12, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers